Implications of Isoniazid Resistance in Mycobacterium bovis Bacillus Calmette-Guerin used for Immunotherapy in Bladder Cancer | Zendy

Matthew Watts | Zendy; Peter C. Taylor | Zendy; Vitali Sintchenko | Zendy; Christopher M. Whelan | Zendy; Rae H. Farnsworth | Zendy; Patrick Jones | Zendy; Peter Jelfs | Zendy; David Carr | Zendy; Hazel Goldberg | Zendy

Open Access

Implications of Isoniazid Resistance in Mycobacterium bovis Bacillus Calmette-Guerin used for Immunotherapy in Bladder Cancer

Author(s) -

Matthew Watts,

Peter C. Taylor,

Vitali Sintchenko,

Christopher M. Whelan,

Rae H. Farnsworth,

Patrick Jones,

Peter Jelfs,

David Carr,

Hazel Goldberg

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciq002

Subject(s) - isoniazid , mycobacterium bovis , medicine , bladder cancer , immunotherapy , bacillus (shape) , microbiology and biotechnology , bcg vaccine , immunology , cancer , mycobacterium tuberculosis , tuberculosis , pathology , vaccination , biology

We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer. Isoniazid resistance in BCG has therapeutic implications when it causes infections after intravesical instillation. For these circumstances, we propose some modifications to existing treatment guidelines for BCG infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research